Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

Sir Demis Hassabis said it feels like a recognition that AI is mature enough now to help with scientific discovery. Read more at straitstimes.com. Read more at straitstimes.com.

We and our 911 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting I Accept enables tracking technologies to support the purposes shown under ...

Demis Hassabis, DeepMind's founder and chief executive, has taken the same roles at Isomorphic Labs on an interim basis, saying in a blog post that the new company will "reimagine the entire drug ...

The start-up – which has emerged from Google parent Alphabet's DeepMind project and is led by DeepMind founder Sir Demis Hassabis – said the financing was led by Thrive Capital, with ...

Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The ...

Google DeepMind CEO Demis Hassabis has said that AI can have a serious crack at solving all diseases in the coming years. And ...

Founded in 2021, Isomorphic Labs is a subsidiary of Google parent Alphabet. It is currently preparing to dose the first patients with the AI-engineered drug in clinical trials and is “staffing up” ...